Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance

BACKGROUND: Although significant advances have been made recently to characterize the biology of pancreatic ductal adenocarcinoma (PDAC), more efforts are needed to improve our understanding and to face challenges related to the aggressiveness, high mortality rate and chemoresistance of this disease...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EBioMedicine
Autors principals: Kaoutari, Abdessamad El, Fraunhoffer, Nicolas A, Hoare, Owen, Teyssedou, Carlos, Soubeyran, Philippe, Gayet, Odile, Roques, Julie, Lomberk, Gwen, Urrutia, Raul, Dusetti, Nelson, Iovanna, Juan
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2021
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8054161/
https://ncbi.nlm.nih.gov/pubmed/33862584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2021.103332
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars